Pay for Performance in Critical Care

A Position Paper by the Society of Critical Care Medicine*

Submitted By: The Pay for Performance Task Force of the Advocacy Committee

Andrew Egol, DO, MBA, FCCM; Aryeh Shander, MD, FCCM; Lisa Kirkland, MD, FACP; Wall, Michael H. MD, FCCM; Todd Dorman, MD, FCCM; Joe Dasta, MSc, FCCM; Sandra Bagwell, MD, FCCM; David Kaufman, MD, FCCM; Paul Matthews, Jr., EdS, RRT, FCCM; Bruce M. Greenwald, MD, FCCM; Daniel L. Herr, MD, MS, FCCM; Cynthia Stavish, RN, MSN, CCRN; Carol Thompson, PhD, FCCM; Brenda G. Fahy, MD, FCCM

Dr. Shander is a consultant for Bayer, Biopure, Hemo Concepts, Inc., NovoNordisk, OrthoBiotech, and Zymognetis; has received grant/research support from Abbott, AstraZeneca, OrthoBiotech, and Zymogenetics; and has received honoraria from Baxter, Bayer, Pfizer, Hemo Concepts, Inc., NovoNordisk, OrthoBiotech, and Zymogenetics. Dr. Dasta has received consulting fees from Hospira, Abbott Point of Care, Vista, and Keimar and honoraria/speaking fees from Hospira and Astellas. The remaining authors have not disclosed any potential conflicts of interest.

*Executive Summary appears in September 2009 issue of Critical Care Medicine (www.ccmjournal.org)